Candice A. Johnstone, MD, MPH

Publications

• Top 10 Tips Palliative Care Clinicians Should Know About Radiation Oncology.

  (Dharmarajan KV, Rich SE, Johnstone CA, Hertan LM, Wei R, Colbert LE, Jones JA, Kamal AH, Jones CA.) J Palliat Med. 2018 Mar;21(3):383-388.

• Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extracranial Irradiation for Extensive-Disease Small Cell Lung Cancer (ED SCLC): NRG Oncology RTOG 0937.

  (Gore EM, Hu C, Sun AY, Grimm DF, Ramalingam SS, Dunlap NE, Higgins KA, Werner-Wasik M, Allen AM, Iyengar P, Videtic GMM, Hales RK, McGarry RC, Urbanic JJ, Pu AT, Johnstone CA, Stieber VW, Paulus R, Bradley JD.) J Thorac Oncol. 2017 10;12(10):1561-1570.

• Preoperative Radiation Therapy Followed by Reexcision May Improve Local Control and Progression-Free Survival in Unplanned Excisions of Soft Tissue Sarcomas of the Extremity and Chest-Wall.

  (Saeed H, King DM, Johnstone CA, Charlson JA, Hackbarth DA, Neilson JC, Bedi M.) Int J Surg Oncol. 2016;2016:5963167.

• External beam radiotherapy and bone metastases.

  (JOHNSTONE C, LUTZ S..) Ann Palliat Med . 2014;3(2):114-122.

• External beam radiotherapy and bone metastases. Bone Matastases: A Translational and Clinical Approach

  (JOHNSTONE C, Lutz S..) . 2nd edition, Chapter 9, December 2013.

• Mesenchymal Tumors: Sarcoma. Gaffney David K., Radiation Oncology: Imaging and Treatment,

  (Wang D, JOHNSTONE C..) 1st ed. Amirsys Publishing, Inc., . 2013, Section 8-2.

• Samarium- 153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases.

  (Longo J, Lutz S, JOHNSTONE C..) Cancer Management and Research . 2013:5 1-8.

• The radiobiology of palliative radiation oncology. Radiation Oncology in Palliative Cancer Care.

  (JOHNSTONE, C..) Edited by Stephen Lutz, Edward Chow, and Peter Hoskin. Radiation Oncology in Palliative Cancer Care. March 2013, 2:15-21 John Wiley & Sons.

• The role of hypofractionated radiation in the management of non-osseous metastatic or uncontrolled local cancer.

  (JOHNSTONE C, Lutz ST..) Ann Palliat Med . Oct 2014;3(4):291-303..

• Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases.

  (Longo J, Lutz S, Johnstone C.) Cancer Manag Res. 2013;5:235-42.

• Negative Predictive Value (NPV) of FDG PET_CT for nodal disease in clinically node-negative early stage lung cancer and identification of risk factors for nodal metastasis.

  (Paravati, A, Seltzer M, Johnstone D, JOHNSTONE C..) Practical Radiation Oncology. .

• Adverse events in the long-term follow-up of patients treated with samarium Sm 153 lexidronam for osseous metastases.

  (Paravati AJ, Russo AL, Aitken C.) Int J Radiat Oncol Biol Phys. 2011 Oct 01;81(2):506-10.